7,651.75

+37.75

+0.50%

52,196.00

+278.00

+0.54%

28,763.00

+229.00

+0.80%

Russell 2000 Futures

2,843.80

+22.50

+0.80%

4.9290

-0.0600

-1.20%

18.86

-0.56

-2.88%

3,905.10

+6.20

+0.16%

77,875.01

-13.09

-0.02%

Crude Oil Dec 26

99.81

-4.31

-4.14%

US Private Equity

10,850.63

-82.20

-0.75%

Taipei Exchange - Delayed Quote TWD

GlycoNex Incorporation (4168.TWO)

21.25 -0.05 (-0.23%)

At close: 1:30:10 PM GMT+8

Loading Chart for 4168.TWO

Chart Range Bar

Interval:

In partnership with ChartIQ

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers

GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers

GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC

GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC

Mobilize your Website

View Site in Mobile | Classic

Share by: